Evidence map›Paper›PMID 40014063›Full record

ReviewBioscience reports2025

Interferon-induced ADP-ribosylation: technical developments driving ICAB discovery.

Victoria Chaves Ribeiro, Lilian Cristina Russo, Dulce María González Duré, Nícolas Carlos Hoch

Abstract readReview
In one paragraph

Review in Bioscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Victoria Chaves RibeiroDepartment of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, Brazil.
Lilian Cristina RussoDepartment of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, Brazil.
Dulce María González DuréDepartment of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, Brazil.
Nícolas Carlos HochDepartment of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-7610-1305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cells respond to a variety of internal and external stimuli by regulating the activities of different signalling cascades and cellular processes, often via chemical modifications of biological macromolecules that modulate their overall levels, biochemical activities or biophysical interactions. One such modification, termed ADP-ribosylation (ADPr), is emerging as an important player in the interferon (IFN) response, but the molecular targets and functions of ADP-ribosyltransferases within this core component of innate immunity still remains unclear. We and others have recently identified that stimulation of IFN signalling cascades promotes the formation of a novel cytosolic structure in human cells that is enriched in ADP-ribosyl modifications. Here, we propose to name these structures 'interferon-induced cytosolic ADPr bodies' (ICABs) and discuss their known components and potential functions. We also review methods to detect ICABs (and cellular ADPr in general) using a range of recently developed reagents. This lays the foundation for future studies aimed at elucidating the molecular functions of ICABs and ADPr in innate immune responses, which is a central unanswered question in the field.

Indexed as

ADP-RibosylationInterferonsADP Ribose TransferasesAnimalsCytosolHumansImmunity, InnateSignal TransductionADP Ribose TransferasesInterferonsADP-ribosylationICABinnate immunityinterferonPARP

Identifiers

PMID40014063
PMCPMC12096948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.